TY - JOUR
T1 - Initial Clinical Experience With Mitral Valve Translocation for Secondary Mitral Regurgitation
AU - Gammie, James S.
AU - Quinn, Rachael W.
AU - Strauss, Erik R.
AU - Wang, Libin
AU - D'Ambra, Michael N.
AU - Hung, Judy
AU - Bernstein, Daniel A.
AU - Tran, Douglas
AU - Rice, Mary Joe K.
AU - Holmes, Sari D.
AU - Pasrija, Chetan
N1 - Funding Information:
This work was supported by patient funding to the Division of Cardiac Surgery, University of Maryland School of Medicine . The authors wish to acknowledge James S. Gammie, Rachael W. Quinn, and Chetan Pasrija are inventors of this method and have submitted disclosures through the University of Maryland.
Funding Information:
This work was supported by patient funding to the Division of Cardiac Surgery, University of Maryland School of Medicine. James S. Gammie, Rachael W. Quinn, and Chetan Pasrija are inventors of this method and have submitted disclosures through the University of Maryland.
Publisher Copyright:
© 2021 The Society of Thoracic Surgeons
PY - 2021/12
Y1 - 2021/12
N2 - Background: Functional (secondary) mitral regurgitation (FMR) results from altered geometry of the mitral valve apparatus. Repair with restrictive mitral annuloplasty is associated with high rates of recurrent mitral regurgitation (MR). We developed a novel operative repair for FMR that translocates the intact mitral valve towards the apex. Methods: The mitral valve was detached circumferentially and translocated into the ventricle with a frustum-shaped glutaraldehyde-treated autologous pericardial patch. Clinical and echocardiographic follow-up was performed. Results: Fifteen consecutive patients with FMR (mean age, 59 years; 67% female) had mitral valve translocation between 2018 and 2020. Preoperative mean ejection fraction, left ventricular end-diastolic dimension, and systolic pulmonary artery pressure were 40% ± 11%, 59 ± 8 mm, and 49 ± 21 mm Hg, respectively; 33% had atrial fibrillation. Cardiomyopathy was ischemic in 4 and nonischemic in 11. Concomitant procedures included tricuspid valve operation (n = 8), coronary artery bypass grafting (n = 4), and atrial fibrillation ablation (n = 5). Post bypass transesophageal echocardiogram demonstrated none/trace MR in all patients and mean gradient of 3 mm Hg (interquartile range, 2-4 mm Hg). Mean leaflet extent of coaptation was 14 ± 2 mm (range, 11-17 mm). There was no postoperative mortality, stroke, or renal failure. Predismissal echocardiography showed none/trace MR in 14 patients and mild MR in 1. One patient underwent successful late rerepair of a suture line leak. Twelve patients were alive at latest follow-up and MR at 1 and 6 months was mild or less in all patients with mean leaflet extent of coaptation of 14 ± 2 mm (range, 12-16 mm) at 6 months. Conclusions: Mitral valve translocation creates a large surface of coaptation and effectively corrects FMR. Further study is needed to demonstrate the long-term durability and clinical utility of this operation.
AB - Background: Functional (secondary) mitral regurgitation (FMR) results from altered geometry of the mitral valve apparatus. Repair with restrictive mitral annuloplasty is associated with high rates of recurrent mitral regurgitation (MR). We developed a novel operative repair for FMR that translocates the intact mitral valve towards the apex. Methods: The mitral valve was detached circumferentially and translocated into the ventricle with a frustum-shaped glutaraldehyde-treated autologous pericardial patch. Clinical and echocardiographic follow-up was performed. Results: Fifteen consecutive patients with FMR (mean age, 59 years; 67% female) had mitral valve translocation between 2018 and 2020. Preoperative mean ejection fraction, left ventricular end-diastolic dimension, and systolic pulmonary artery pressure were 40% ± 11%, 59 ± 8 mm, and 49 ± 21 mm Hg, respectively; 33% had atrial fibrillation. Cardiomyopathy was ischemic in 4 and nonischemic in 11. Concomitant procedures included tricuspid valve operation (n = 8), coronary artery bypass grafting (n = 4), and atrial fibrillation ablation (n = 5). Post bypass transesophageal echocardiogram demonstrated none/trace MR in all patients and mean gradient of 3 mm Hg (interquartile range, 2-4 mm Hg). Mean leaflet extent of coaptation was 14 ± 2 mm (range, 11-17 mm). There was no postoperative mortality, stroke, or renal failure. Predismissal echocardiography showed none/trace MR in 14 patients and mild MR in 1. One patient underwent successful late rerepair of a suture line leak. Twelve patients were alive at latest follow-up and MR at 1 and 6 months was mild or less in all patients with mean leaflet extent of coaptation of 14 ± 2 mm (range, 12-16 mm) at 6 months. Conclusions: Mitral valve translocation creates a large surface of coaptation and effectively corrects FMR. Further study is needed to demonstrate the long-term durability and clinical utility of this operation.
UR - http://www.scopus.com/inward/record.url?scp=85112493335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112493335&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2020.12.032
DO - 10.1016/j.athoracsur.2020.12.032
M3 - Article
C2 - 33440174
AN - SCOPUS:85112493335
SN - 0003-4975
VL - 112
SP - 1946
EP - 1953
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 6
ER -